Platelet activation in acute, decompensated congestive heart failure

Area of Science:

• Cardiology
• Hematology
• Biomedical Science

Background:

• Congestive heart failure (CHF) increases risks for thromboembolism, stroke, and sudden death, potentially due to thrombogenesis and platelet activation abnormalities.
• A detailed assessment of platelet function in acute decompensated heart failure (AHF) is needed to understand these risks.
• This study hypothesizes greater platelet index abnormalities in AHF patients compared to stable CHF and healthy controls.

Purpose of the Study:

• To comprehensively assess platelet (dys)function in patients with acute decompensated heart failure (AHF).
• To compare platelet indices in AHF patients with those in stable congestive heart failure (CHF) and healthy controls.
• To evaluate the impact of AHF treatment on platelet activation markers.

Main Methods:

• Measured soluble P-selectin (sP-sel) using ELISA.
• Assessed platelet surface P-selectin (CD62P%G) and CD63%G expression via flow cytometry.
• Analyzed platelet structural indices: mean platelet volume (MPV), mean platelet mass (MPM), and mean platelet component (MPC) in 22 AHF patients (pre- and post-treatment), 68 stable CHF patients, and 23 healthy controls.

Main Results:

• Significant differences were observed in MPV, MPC, platelet surface P-selectin (CD62P%G), and CD63%G across the three groups.
• AHF patients exhibited higher platelet surface P-selectin compared to stable CHF patients and healthy controls.
• Platelet surface P-selectin, CD63, and CD40L significantly decreased after AHF treatment, while platelet morphology and sP-sel levels remained unchanged.

Conclusions:

• Patients with AHF demonstrate distinct platelet activation abnormalities compared to stable CHF patients and healthy individuals.
• Treatment for AHF effectively modifies certain platelet activation markers.
• These findings suggest that platelet activation may contribute to the pathophysiology of adverse complications in AHF.